logo-loader
viewGenetic Technologies

Genetic Technologies heads to market

au_australiancash350_54f8d9611af02.jpg

Genetic Technologies (ASX:GTG, NASDAQ:GENE) is preparing to reveal details of a capital raising. The ASX has granted the company a trading halt to organise.

GTG is a molecular diagnostics company, with its lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.

The halt will remain in place until the opening of trade on Tuesday 10th March 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Genetic Technologies

Price: 0.005 AUD

ASX:GTG
Market: ASX
Market Cap: $36.07 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Next Green Wave sees impressive revenue numbers as the company becomes...

Next Green Wave (CSE: NGW- OTCQX: NXGWF) CEO Mike Jennings joined Steve Darling from Proactive Vancouver with news the company has released very positive financial number that has seen them become profitable in the last 3 months. Jennings talks about what has led the company to that milestone...

1 day, 11 hours ago

2 min read